增殖性糖尿病视网膜病变围手术期玻璃体腔内注射康柏西普的疗效研究

Study on the Effect of Conbercept Intravitreal Injection for Proliferative Diabetic Retinopathy at Perioperative Period

摘要: 目的：对比观察单行玻璃体切除术(Pars Plana vitrectomy, PPV)与玻璃体腔内注射康柏西普联合玻璃体切除术治疗增殖性糖尿病视网膜病变(Proliferative diabetic retinopathy, PDR)的临床效果。方法：选取我院2014-12/2015-12收治的PDR患者23例26眼，随机分为两组。单行PPV治疗的患者为对照组(11例12眼)，在行PPV术前行康柏西普玻璃体腔内注射的患者为试验组(12例14眼)。术后随访1年，观察两组患者手术情况及治疗效果。结果：试验组的平均手术时间、术中严重出血率均少于对照组。两组患者术前CMT、BCVA差异无统计学意义，术后试验组明显优于对照组，且差异具有统计学意义。结论：行PPV前玻璃体腔内注射康柏西普可以有效的缩短手术时间，减少术中出血，降低医源性裂孔的发生率，减轻黄斑水肿，提高患者的最佳矫正视力。

Abstract: AIM: To compare the effects of pars plana vitrectomy (PPV) with or without conbercept intravitreal injection of proliferative diabetic retinopathy (PDR). METHODS: 23 patients (26 eyes) with PDR in our hospital from December 2014 to December 2015 were recruited, and were randomly divided into two groups. 11 cases (12 eyes) in control group were received single vitrectomy. In ex-perimental group, 12 cases (14 eyes) were injected by drug therapy of conbercept and received vitrectomy. In the postoperative follow-up of 1 year, the general situation of operation and thera-peutic effect between the two groups were analyzed. RESULTS: The average operation time, bleeding during operation of the experimental group were lower than that of the control group; they were significantly different. There was no statistically significant difference between two groups on CMT & BCVA before operation, but the experimental group had better effect than control group at 4mo. CONCLUSION: Intravitreal injection of conbercept before vitrectomy can decrease the operation time, reduce active neovascularization, minimize the incidence of intraoperative haemorrhage and iatrogenic retinal breaks incidence, alleviate macular edema and improve BCVA of patients in the treatment of PDR.